

Substitute for form 144B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Complete if Known						
Application Number	10/561,449					
Filing Date	December 20, 2005					
First Named Inventor	Luc Bouwens et al.					
Art Unit	1647					
Examiner Name	Daniel C. Gamett					
Attomey Docket Number	BOUW3001/JEK					

						Examine Name	Darliel C. Garriell	
Sheet		1	of	T	3	Attomey Docket Number	BOUW3001/JEK	
			NO	N PA	TENT LITERA	TURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		Europea 73 7673	Search R	eport	t dated Novembe	er 16, 2007 relating to Europ	pean Application EP 04	
		RAMIYA K. VIJAYAKUMAKUMAR ET AL., "Reversal of insufin-dependent diabetes using listets generated in vitro from pancreatic stem cells", <u>Nature Medicine</u> , <u>Nature America</u> , Vol. 6, No. 3, March 2000 (2000-03) pages 278-282, XP000864764						
	HIROSATO MASHIMA ET AL. "Beboellulin and Activin A Coordinately Convert Amylase- secreting Pancreatic AR421 Cells into insulin-secreting Cells", <u>Journal of Colinical</u> Investigation, Vol. 97, No. 7, April 1996 (1996-0-01), pages 1647-1657, XP000670303							
	KI-HO SONG ET AL., "In vitro transdifferentiation of adult pancreatic acinar cells into in expressing cells", <u>Biochemical and Biochysical Research Communications</u> , Vol. 316, N April 16, 2004 (2004-04-16), pages 1094-1100, XP004495901							
		an Exper	imental Mo	del o	of Diabetes", End	Pancreatic & Cells from Introduction Pancreatic & Cells from Introduction (No. 11 No.		
						ancreatic acinoductal transd a, Springer-Velag 2000, Vol		
						t of Gastrin and Expression enterology, Vol. 123, 2001, p		
		From Tra		ated	but Not From N	tes ß Cell Neogenesis and lormal Exocrine Pancreas T		
•						ne Intermediate Cells in Str bl, Vol. 15, No. 3, 1997, pag		
					, "Pluripotency o 8, July 2002, pa	f mesenchymal stem cells o	derived from adult	

		The state of the s
Examiner Signature	/Daniel Gamett/ (09/29/2008)	Date , Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application Confidentiality is governed by 38 U.S.C. 1.22 and 37 CFR 1.14. This collection is destinated to take you have to complete, finduling pathemapting the completed application from the USPTO. Time will vary deporting upon the individual case. Any comments on the second for the your equire to complete this form and/or suggestions of recoursing this process, about the series for the Credit Information Confidence (See Technology Confidence). Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144B/PTO		Complete if Known						
Substitute for form 1446/F (O			Application Number	10/561,449				
INI	EOD!	ATION DISCL	OCUBE	Filing Date	December 20, 2005			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many shoots as necessary)			First Named Inventor	Luc Bouwens et al.				
				Art Unit	1647	_		
	,	,	,,,	Examiner Name	Daniel C. Gamett	_		
Sheet		2 of	3	Attomey Docket Number	BOUW3001/JEK	_		
		NO	PATENT LITERAT	TURE DOCUMENTS				
Examiner nitials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
			ic Cells In Vitro: A Ba	oidermal Growth Factor Increa alance Between Proliferation : -1579				
				nigration and delayed differen , <u>Development</u> , Vol. 127, 200		Γ		
KOJI YAMAMOTO ET AL., "Recombinant Human Betacellulin Promotes the Neogenesis Cells and Ameliorates Glucose Intolerance in Mice With Diabetes Induced by Selective Alloxan Perfusion." Diabetes. Vol. 40, December 2000, pages 2021-2027					iced by Selective			
EUGENIO BERTELLI ET AL., "Intermonditions", American Physiological S				liate endocrine-acinar pancreatic cells in duct ligation iety, Vol. 273, 1997, pages 1641-1649				
		SUSAN BONNER-WEIR ET AL., "In vitro cultivation of human islets from expanded ductal tissue, PNAS, Vol. 97, No. 14, July 5, 2000, pages 7999-8004						
		LUC BOWENS. "Transdifferentiation Versus Stem Cell Hypothesis for the Regeneration of Islet Beta-Cells in the Pancreas", <u>Microscopy Research And Technique</u> , Vol. 43, 1998, pages 32-336						
		LUC BOWENS ET A 427, pages 553-560	L., "Islet cell neogen	esis in the pancreas", Biome	dische-Bibl, 1996, Vol.			
			generation with Syst	ological Treatment of Chronic emic Co-administration of EG 00, pages 414-420				
		JEAN BUTEAU ET / Transactivation of the pages 124-132	AL., "Glucagon-Like I ne Epidermal Growth	Peptide 1 Induces Pancreatic Factor Receptor", <u>Diabetes</u> ,	β-Cell Proliferation Via Vol. 52, January 2003,			
				Peptides: Regulators of Cell P				

Examiner /Daniel Gamett/ (09/29/2008)	Date Considered
---------------------------------------	--------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is

attached.

attached. Indication of information is required by 3T CFR, 197 and 1.98. The information is required to aboin or relain a boreful by the golden which is fine closely be in the SEPTO by protection in explaints on explaints. In this collection is a registration. Cell of the second of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 144B/PTO			Complet	e if Known			
			Application Number	10/561,449			
			Filing Date	December 20, 2005			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)					First Named Inventor	Luc Bouwens et al.	
					Art Unit 1647		
(Use as many sneets as necessary)			Examiner Name	Daniel C. Gamett			
Sheet		3	of	3	Attorney Docket Number	BOUW3001/JEK	
			NON	PATENT LITERAT	TURE DOCUMENTS		
Examiner Initials*	Cite No.1	of the item (b volume-issue HELENA EDI	ook, ma numbe	agazine, journal, señ r(s), publisher, city a 'Pancreatic Organog	ETTERS), title of the article al, symposium, catalog, etc.), ndfor country where publishe enests - Developmental Med I, July 2002, pages 524-532	date, page(s), d.	T2
						*	

.

Examiner Signature /Daniel Gamett/ (09/29/2008) Date Considered

[&]quot;EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 600, Draw line through classion if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

attacation. Conformation is required by 37 CER, 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to this (and by the USPTO to procease) an application. Conformatishly is oper